Comparison of Nephron-protective Effects of Enalapril and GLP Analogues (Exenatide) in Diabetic Nephropathy

Abstract

Background: One of the major concerns is a nephropathy in diabetes, which applies many different kinds of medicines. However, required level of the treatment of renal disease has not been achieved.

Aim: To investigate and compare the effect of the enalapril and the exenatide on diabetic nephropathy in rats developed diabetes by streptozosin.

Material and Methods: 32 male Sprague Dawley rats were divided into 4 groups: (1) Control, (2) Diabetic (DM), (3) DM+ Enalapril, and (4) DM+ exenatide groups. Then, the animals were euthanized and their blood samples were collected by cardiac puncture for blood glucose; blood urea nitrogen (BUN), creatinin, and nephrectomy were performed for histopathologic examination, and urine samples were taken on stick for proteinuria.

Results: Administration of the enalapril or the exenatide in diabetic rats resulted in a significant reduction both fibronectin, induced nitric oxide synthase (i-NOS) expression in glomerular area and urine protein levels. It was shown that both of enalapril and exenatide protected the renal glomerulus more than diabetic group in the nephropathy histopathologically.

Conclusion: The beneficial effects of enalapril and exenatide which reduces fibronectin, i-NOS expression and urine protein levels or increases recovery of glomerules, might be used for preventing the harmful effects of diabetic nephropathy.

Key words

medicine - biochemical - histopathological - enalapril - exenatide - diabetes

• References

• 1 Gross JL, de Azevedo MJ, Silveiro SP et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005; 28: 164-176
• 2 Chaturvedi N, Bandinelli S, Mangili R et al. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 2001; 60: 219-227
• 3 Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225 -232
• 4 Parving HH, Hommel E, Mathiesen E et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med J (Clin Res Ed) 1988; 296: 156
• 5 Nieuwdorp M, van Haeften TW, Gouverneur M et al. Loss of endothelial glycocalyx during acute hyperglycemia. Diabetologia 2008; 51: 714-725
• 6 Weir MR. Differing effects of antihypertensive agents on urinary albumin excretion. Am J Nephrol 1996; 16: 237-245
• 7 Salvetti A, Mattei P, Sudano I. Renal protection and antihypertensive drugs. Drugs 1999; 57: 665-693
• 8 Lacourcière Y, Nadeau A, Poirier L et al. Captopril or conventional therapy in hypertensive type II diabetics: Three year analysis. Hypertension 1993; 21: 786-794
• 9 Sano T, Kawamura T, Matsumae H et al. Effects of long-term enalapril treatment on persistent microalbuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care 1994; 17: 420-424
• 10 Leoncini G, Viazzi F, Pontremoli R. Chronic kidney disease and albuminuria in arterial hypertension. Curr Hypertens Rep 2010; 12: 335-341
• 11 Elrick H, Stimmler L, Hlad Jr CJ et al. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964; 24: 1076-1082
• 12 Raufman JP, Singh L, Singh G et al. Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. J Biol Chem 1992; 267: 21432-21437
• 13 Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 1992; 89: 8641-8645
• 14 Ban K, Noyan A, Shraf MH et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008; 117: 2340-2350
• 15 Park CW, Kim HW, Ko SH et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 2007; 18: 1227-1238
• 16 Gerich J. DPP-4 inhibitors: what may be the clinical differentiators?. Diabetes Research and Clinical Practice 2010; 90: 131-140
• 17 Yang J, Zeng Z, Wu T et al. Emodin attenuates high glucose-induced TGF-β1and fibronectin expression in mesangialcells through inhibition of NF-κB pathway. Exp Cell Res 2013; 319: 3182-3189
• 18 Jackson B, Cubela R, Debrevi L et al. Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat. J Cardiovasc Pharmacol 1987; 10: 167-169
• 19 Hu G, Zhang Y, Jiang H et al. Exendin-4 attenuates myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein expression. Cardiol J 2013; 20: 600-604
• 20 Pagana KD, Pagana TJ. Urine studies. In: Pagana KD, Pagana TJ. (eds.). Mosby’s Manual of Diagnostic and Laboratory Tests. 2^nd (ed.). St. Louis, MO: Mosby; 2002: 811-880
• 21 Simerville JA, Maxted WC, Pahira JJ. Urinalysis: a comprehensive review [published correction appears in Am Fam Physician. 2006; 74: 1096]. Am Fam Physician 2005; 71: 1153-1162
• 22 Pietrow PK, Karellas ME. Medical management of common urinary calculi. Am Fam Physician 2006; 74: 86-94
• 23 Grossfeld GD, Wolf Jr JS, Litwan MS et al. Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations. Am Fam Physician 2001; 63: 1145-1154
• 24 Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19: 403-418
• 25 The National High Blood Pressure Education Program Working Group . National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994; 23: 145-158
• 26 Hannedouche T, Landais P, Goldfarb B et al. Randomized controlled trial of enalapril and beta blockers in nondiabetic chronic renal failure. BMJ 1994; 309: 833-837
• 27 Kamper AL, Strandgaard S, Leyssac PP. Effect of enalapril on the progression of chronic renal failure: a randomized controlled trial. Am J Hypertens 2002; 5: 423-430
• 28 Maschio G, Alberti D, Janin G et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334: 939-945
• 29 Akishita M, Nagai K, Xi H et al. Renin-angiotensin system modulates oxidative stress-induced endothelial cell apoptosis in rats. Hypertension 2005; 45: 1188-1193
• 30 Zafari AM, Ushio-Fukai M, Akers M et al. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension 1998; 32: 488-495
• 31 Vaziri ND, Ni Z, Oveisi F et al. Effect of antioxidant therapy on blood pressure and NO synthase expression in hypertensive rats. Hypertension 2000; 36: 957-964
• 32 Vaziri ND, Ding Y, Ni Z. Compensatory up-regulation of nitric oxide synthase isoforms in lead-induced hypertension; reversal by a superoxide dismutase-mimetic drug. J Pharmacol Exp Ther 2001; 298: 679-685
• 33 Broadbent NV, Stahl PJ, Chen J et al. Early upregulation of iNOS mRNA expression and increase in NO metabolites in pressurized renal epithelial cells. Am J Physiol Renal Physiol 2007; 293: 1877-1888
• 34 Sharma R, Sharma M, Reddy S et al. Chronically increased intrarenal angiotensin II causes nephropathy in an animal model of type 2 diabetes. Front Biosci 2006; 1; 11: 968-976
• 35 Comper WD, Hilliard LM, Nikolic-Paterson DJ et al. Disease-dependent mechanisms of albuminuria. American Journal of Physiology 2008; 295: 1589-1600
• 36 Ciechanowicz A. Molecular mechanisms of nephro-protective action of enalapril in experimental chronic renal failure. Ann Acad Med Stetin 1999; 52: 1-93
• 37 Noh H, Ha H, Yu MR et al High glucose increases inducible NO production in cultured rat mesangial cells. Possible role in fibronectin production. Nephron 2002; 90: 78-85
• 38 Liu XH, Wang YP, Wang LX et al. Exendin-4 protects murine MIN6 pancreatic β-cells from interleukin-1β-induced apoptosis via the NF-κB pathway. J Endocrinol Invest 2013; 18
• 39 Hocher B, Reichetzeder C, Alter ML. Renal and cardiac effects of DPP4 inhibitors-from preclinical development to clinical research. Kidney & Blood Pressure Research 2012; 36: 65-84
• 40 Lazzara MJ, Deen WM. Model of albumin reabsorption in the proximal tubule. American Journal of Physiology 2007; 292: 430-439
• 41 Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium?. Diabetologia 2008; 51: 714-725
• 42 Nieuwdorp M, van Haeften TW, Gouverneur MC et al. Loss of endothelial glycocalyx during acute hyperglycemia. Diabetologia 2008; 51: 714-725
• 43 Lemley KV, Blouch K, Abdullah I et al. Glomerular permselectivity at the onset of nephropathy in type 2 diabetes mellitus. Journal of the American Society of Nephrology 2000; 11: 2095-2105
• 44 Pavenstädt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiological Reviews 2003; 83: 253-307
• 45 Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996; 137: 2968-2978
• 46 Erdogdu Ö, Nathanson D, Sjöholm Å et al. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Molecular and Cellular Endocrinology 2010; 325: 26-35
• 47 Kodera R, Shikata K, Kataoka HU et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011; 54: 965-978
• 48 Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascular Pharmacology 2011; 55: 10-16
• 49 Shah Z, Pineda C, Kampfrath T et al. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascular Pharmacology 2011; 55: 2-9
• 50 Mega C, de Lemos ET, Vala H et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Experimental Diabetes Research 2011; 2011: 162092
• 51 Liu WJ, Xie SH, Liu YN et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. Journal of Pharmacology and Experimental Therapeutics 2012; 340: 248-255
• 52 Alter ML, Ott IM, von Websky K et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney and Blood Pressure Research 2012; 36: 119-130
• 53 Hendarto H, Inoguchi T, Maeda Y et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism 2012; 61: 1422-1434
• 54 Mazze RS, Bergenstal R, Ginsberg B. Intensified diabetes management: lessons from the diabetes control and complications trial. International Journal of Clinical Pharmacology and Therapeutics 1995; 33: 43-51
• 55 Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British Medical Journal 2000; 321: 405-412
• 56 Zhang H, Zhang X, Hu C et al. Exenatide reduces urinary transforming growth factor-1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria. Kidney and Blood Pressure Research 2012; 35: 483-488
• 57 Li L, El-Kholy W, Rhodes CJ et al. Glucagon-like leptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia 2005; 48: 1339-1349
• 58 Ruggenenti P, Perna A, Gherardi G et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998; 352: 1252-1256
• 59 Apperloo AJ, De Zeeuw D, Sluiter HE et al. Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. BMJ 1991; 303: 821-824